PMID- 37705761
OWN - NLM
STAT- MEDLINE
DCOM- 20230915
LR  - 20230916
IS  - 1661-8564 (Electronic)
IS  - 1661-8556 (Print)
IS  - 1661-8556 (Linking)
VI  - 68
DP  - 2023
TI  - Deficiencies in the Recognition and Reporting of Chronic Kidney Disease in 
      Patients With Type 2 Diabetes Mellitus; A Hungarian Nationwide Analysis.
PG  - 1606151
LID - 10.3389/ijph.2023.1606151 [doi]
LID - 1606151
AB  - Objectives: Recognition of chronic kidney disease (CKD) is crucial in type 2 
      diabetes mellitus (T2DM). We conducted a nationwide epidemiological study to 
      evaluate T2DM-associated CKD in Hungary between 2016 and 2020. Methods: Annual 
      incidence and prevalence rates of registered CKD amongst all pharmacologically 
      treated T2DM patients were analyzed in different age-groups by the central 
      database of the Hungarian Health Insurance Fund Management. Statistical methods 
      included Poisson regression, Bonferroni test, Chi-square test. Results: We found 
      499,029 T2DM patients and 48,902 CKD patients in 2016, and 586,075 T2DM patients 
      and 38,347 CKD patients in 2020. The majority of all prevalent T2DM and CKD 
      patients were older (aged 60-69 years: 34.1% and 25.8%; >/=70 years: 36.1% and 
      64.4%, respectively). The annual incidence of T2DM and incidence rates of CKD in 
      T2DM decreased in 2017-2020 (p < 0.001). The annual prevalence of T2DM increased 
      (p < 0.01), the prevalence rates of CKD in T2DM were low and decreased from 9.8% 
      to 6.5% in 2016-2020 (p < 0.001). Conclusion: Incidence and prevalence of 
      T2DM-associated CKD decreased significantly in Hungary in 2016-2020. Lower 
      prevalence rates of CKD may suggest under-recognition and/or under-reporting.
CI  - Copyright (c) 2023 Ladanyi, Salfer, Balla, Karpati, Reusz, Szabo, Andriska, Nemeth, 
      Wittmann and Laczy.
FAU - Ladanyi, Erzsebet
AU  - Ladanyi E
AD  - Fresenius Medical Care Nephrology Center, Miskolc, Hungary.
FAU - Salfer, Balazs
AU  - Salfer B
AD  - AstraZeneca Ltd., Budapest, Hungary.
FAU - Balla, Jozsef
AU  - Balla J
AD  - Department of Nephrology, Institute of Internal Medicine, Faculty of Medicine, 
      University of Debrecen, Debrecen, Hungary.
FAU - Karpati, Istvan
AU  - Karpati I
AD  - Department of Nephrology, Institute of Internal Medicine, Faculty of Medicine, 
      University of Debrecen, Debrecen, Hungary.
FAU - Reusz, Gyorgy
AU  - Reusz G
AD  - First Department of Pediatrics, Semmelweis University, Budapest, Hungary.
FAU - Szabo, Lilla
AU  - Szabo L
AD  - AstraZeneca Ltd., Budapest, Hungary.
FAU - Andriska, Peter
AU  - Andriska P
AD  - Healthware Consulting Ltd., Budapest, Hungary.
FAU - Nemeth, Laszlo
AU  - Nemeth L
AD  - Healthware Consulting Ltd., Budapest, Hungary.
FAU - Wittmann, Istvan
AU  - Wittmann I
AD  - Second Department of Medicine and Nephrology-Diabetes Center, University of Pecs 
      Medical School, Pecs, Hungary.
FAU - Laczy, Boglarka
AU  - Laczy B
AD  - Second Department of Medicine and Nephrology-Diabetes Center, University of Pecs 
      Medical School, Pecs, Hungary.
LA  - eng
PT  - Journal Article
DEP - 20230829
PL  - Switzerland
TA  - Int J Public Health
JT  - International journal of public health
JID - 101304551
SB  - IM
MH  - Humans
MH  - *Diabetes Mellitus, Type 2/epidemiology
MH  - Hungary/epidemiology
MH  - Databases, Factual
MH  - Insurance, Health
MH  - *Renal Insufficiency, Chronic/epidemiology
PMC - PMC10496514
OTO - NOTNLM
OT  - Hungary
OT  - chronic kidney disease
OT  - prevalence
OT  - type 2 diabetes mellitus
OT  - under-reporting
COIS- BS and LS are full time employees of AstraZeneca Hungary Ltd. Authors PA and LN 
      were employed by the company Healthware Consulting Ltd. The remaining authors 
      declare that they do not have any conflicts of interest. The study was delivered 
      with the financial support of AstraZeneca. In this retrospective epidemiological 
      study, no drugs were supplied or funded. The funder had the following involvement 
      with the study: concept, design, and data collection; additionally an AstraZeneca 
      team reviewed this manuscript for scientific accuracy during its development and 
      was allowed to make suggestions.
EDAT- 2023/09/14 06:42
MHDA- 2023/09/15 06:42
PMCR- 2023/08/29
CRDT- 2023/09/14 04:06
PHST- 2023/05/02 00:00 [received]
PHST- 2023/08/17 00:00 [accepted]
PHST- 2023/09/15 06:42 [medline]
PHST- 2023/09/14 06:42 [pubmed]
PHST- 2023/09/14 04:06 [entrez]
PHST- 2023/08/29 00:00 [pmc-release]
AID - 1606151 [pii]
AID - 10.3389/ijph.2023.1606151 [doi]
PST - epublish
SO  - Int J Public Health. 2023 Aug 29;68:1606151. doi: 10.3389/ijph.2023.1606151. 
      eCollection 2023.